Search Results - "Connors, Joseph M"

Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment by Steidl, Christian, Connors, Joseph M, Gascoyne, Randy D

“…Hodgkin's lymphoma (HL) represents the most common subtype of malignant lymphoma in young people in the Western world. Most patients can be cured with modern…”
Get more information

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma by Ennishi, Daisuke, Jiang, Aixiang, Boyle, Merrill, Collinge, Brett, Grande, Bruno M, Ben-Neriah, Susana, Rushton, Christopher, Tang, Jeffrey, Thomas, Nicole, Slack, Graham W, Farinha, Pedro, Takata, Katsuyoshi, Miyata-Takata, Tomoko, Craig, Jeffrey, Mottok, Anja, Meissner, Barbara, Saberi, Saeed, Bashashati, Ali, Villa, Diego, Savage, Kerry J, Sehn, Laurie H, Kridel, Robert, Mungall, Andrew J, Marra, Marco A, Shah, Sohrab P, Steidl, Christian, Connors, Joseph M, Gascoyne, Randy D, Morin, Ryan D, Scott, David W

“…High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) has a poor outcome after standard chemoimmunotherapy. We sought to…”
Get more information

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study by Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L, Rosenblatt, Joseph D, Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M, Yang, Yin, Sievers, Eric L, Kennedy, Dana A, Shustov, Andrei

“…Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug…”
Get more information

Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors by Mak, Vivien, Hamm, Jeremey, Chhanabhai, Mukesh, Shenkier, Tamara, Klasa, Richard, Sehn, Laurie H, Villa, Diego, Gascoyne, Randy D, Connors, Joseph M, Savage, Kerry J

“…A number of novel therapies are under investigation in relapsed or refractory peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is…”
Get more information

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition by Ennishi, Daisuke, Takata, Katsuyoshi, Béguelin, Wendy, Duns, Gerben, Mottok, Anja, Farinha, Pedro, Bashashati, Ali, Saberi, Saeed, Boyle, Merrill, Meissner, Barbara, Ben-Neriah, Susana, Woolcock, Bruce W, Telenius, Adèle, Lai, Daniel, Teater, Matt, Kridel, Robert, Savage, Kerry J, Sehn, Laurie H, Morin, Ryan D, Marra, Marco A, Shah, Sohrab P, Connors, Joseph M, Gascoyne, Randy D, Scott, David W, Melnick, Ari M, Steidl, Christian

“…We performed a genomic, transcriptomic, and immunophenotypic study of 347 patients with diffuse large B-cell lymphoma (DLBCL) to uncover the molecular basis…”
Get more information

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies by Scott, David W, Mottok, Anja, Ennishi, Daisuke, Wright, George W, Farinha, Pedro, Ben-Neriah, Susana, Kridel, Robert, Barry, Garrett S, Hother, Christoffer, Abrisqueta, Pau, Boyle, Merrill, Meissner, Barbara, Telenius, Adele, Savage, Kerry J, Sehn, Laurie H, Slack, Graham W, Steidl, Christian, Staudt, Louis M, Connors, Joseph M, Rimsza, Lisa M, Gascoyne, Randy D

“…To evaluate the prognostic impact of cell-of-origin (COO) subgroups, assigned using the recently described gene expression-based Lymph2Cx assay in comparison…”
Get more information

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma by Younes, Anas, Gopal, Ajay K, Smith, Scott E, Ansell, Stephen M, Rosenblatt, Joseph D, Savage, Kerry J, Ramchandren, Radhakrishnan, Bartlett, Nancy L, Cheson, Bruce D, de Vos, Sven, Forero-Torres, Andres, Moskowitz, Craig H, Connors, Joseph M, Engert, Andreas, Larsen, Emily K, Kennedy, Dana A, Sievers, Eric L, Chen, Robert

“…Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing…”
Get more information

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population by Alduaij, Waleed, Collinge, Brett, Ben-Neriah, Susana, Jiang, Aixiang, Hilton, Laura K, Boyle, Merrill, Meissner, Barbara, Chong, Lauren, Miyata-Takata, Tomoko, Slack, Graham W, Farinha, Pedro, Craig, Jeffrey W, Lytle, Andrew, Savage, Kerry J, Villa, Diego, Gerrie, Alina S, Freeman, Ciara L, Gascoyne, Randy D, Connors, Joseph M, Morin, Ryan D, Sehn, Laurie H, Mungall, Andrew J, Steidl, Christian, Scott, David W

“…Molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) underlies the variable outcomes achieved with immunochemotherapy. However, outcomes of gene…”
Get more information

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy by Jurinovic, Vindi, Kridel, Robert, Staiger, Annette M, Szczepanowski, Monika, Horn, Heike, Dreyling, Martin H, Rosenwald, Andreas, Ott, German, Klapper, Wolfram, Zelenetz, Andrew D, Barr, Paul M, Friedberg, Jonathan W, Ansell, Stephen, Sehn, Laurie H, Connors, Joseph M, Gascoyne, Randy D, Hiddemann, Wolfgang, Unterhalt, Michael, Weinstock, David M, Weigert, Oliver

“…Follicular lymphoma (FL) is a clinically and molecularly heterogeneous disease. Posttreatment surrogate end points, such as progression of disease within 24…”
Get more information

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study by Younes, Anas, Connors, Joseph M, Park, Steven I, Fanale, Michelle, O'Meara, Megan M, Hunder, Naomi N, Huebner, Dirk, Ansell, Stephen M

“…Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and…”
Get full text

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue by Scott, David W, Wright, George W, Williams, P Mickey, Lih, Chih-Jian, Walsh, William, Jaffe, Elaine S, Rosenwald, Andreas, Campo, Elias, Chan, Wing C, Connors, Joseph M, Smeland, Erlend B, Mottok, Anja, Braziel, Rita M, Ott, German, Delabie, Jan, Tubbs, Raymond R, Cook, James R, Weisenburger, Dennis D, Greiner, Timothy C, Glinsmann-Gibson, Betty J, Fu, Kai, Staudt, Louis M, Gascoyne, Randy D, Rimsza, Lisa M

“…The assignment of diffuse large B-cell lymphoma into cell-of-origin (COO) groups is becoming increasingly important with the emergence of novel therapies that…”
Get more information

Older patients (aged 60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: A detailed analysis from the phase III ECHELON-1 study by Evens, Andrew M., Connors, Joseph M., Younes, Anas, Ansell, Stephen M., Kim, Won Seog, Radford, John, Feldman, Tatyana, Tuscano, Joseph, Savage, Kerry J., Oki, Yasuhiro, Grigg, Andrew, Pocock, Christopher, Dlugosz-Danecka, Monika, Fenton, Keenan, Forero-Torres, Andres, Liu, Rachael, Jolin, Hina, Gautam, Ashish, Gallamini, Andrea

“…Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma. We report results for older patients with classical Hodgkin…”
Get full text

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL by Savage, Kerry J, Slack, Graham W, Mottok, Anja, Sehn, Laurie H, Villa, Diego, Kansara, Roopesh, Kridel, Robert, Steidl, Christian, Ennishi, Daisuke, Tan, King L, Ben-Neriah, Susana, Johnson, Nathalie A, Connors, Joseph M, Farinha, Pedro, Scott, David W, Gascoyne, Randy D

“…Dual expression of MYC and BCL2 by immunohistochemistry (IHC) is associated with poor outcome in diffuse large B-cell lymphoma (DLBCL). Dual translocation of…”
Get more information

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone by Johnson, Nathalie A, Slack, Graham W, Savage, Kerry J, Connors, Joseph M, Ben-Neriah, Susana, Rogic, Sanja, Scott, David W, Tan, King L, Steidl, Christian, Sehn, Laurie H, Chan, Wing C, Iqbal, Javeed, Meyer, Paul N, Lenz, Georg, Wright, George, Rimsza, Lisa M, Valentino, Carlo, Brunhoeber, Patrick, Grogan, Thomas M, Braziel, Rita M, Cook, James R, Tubbs, Raymond R, Weisenburger, Dennis D, Campo, Elias, Rosenwald, Andreas, Ott, German, Delabie, Jan, Holcroft, Christina, Jaffe, Elaine S, Staudt, Louis M, Gascoyne, Randy D

“…Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone…”
Get more information

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma by Gopal, Ajay K, Chen, Robert, Smith, Scott E, Ansell, Stephen M, Rosenblatt, Joseph D, Savage, Kerry J, Connors, Joseph M, Engert, Andreas, Larsen, Emily K, Chi, Xuedong, Sievers, Eric L, Younes, Anas

“…We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory…”
Get more information

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma by Mottok, Anja, Hung, Stacy S, Chavez, Elizabeth A, Woolcock, Bruce, Telenius, Adèle, Chong, Lauren C, Meissner, Barbara, Nakamura, Hisae, Rushton, Christopher, Viganò, Elena, Sarkozy, Clementine, Gascoyne, Randy D, Connors, Joseph M, Ben-Neriah, Susana, Mungall, Andrew, Marra, Marco A, Siebert, Reiner, Scott, David W, Savage, Kerry J, Steidl, Christian

“…Primary mediastinal large B-cell lymphoma (PMBL) represents a clinically and pathologically distinct subtype of large B-cell lymphomas. Furthermore, molecular…”
Get more information

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin by Morin, Ryan D, Johnson, Nathalie A, Severson, Tesa M, Mungall, Andrew J, An, Jianghong, Goya, Rodrigo, Paul, Jessica E, Boyle, Merrill, Woolcock, Bruce W, Kuchenbauer, Florian, Yap, Damian, Humphries, R Keith, Griffith, Obi L, Shah, Sohrab, Zhu, Henry, Kimbara, Michelle, Shashkin, Pavel, Charlot, Jean F, Tcherpakov, Marianna, Corbett, Richard, Tam, Angela, Varhol, Richard, Smailus, Duane, Moksa, Michelle, Zhao, Yongjun, Delaney, Allen, Qian, Hong, Birol, Inanc, Schein, Jacqueline, Moore, Richard, Holt, Robert, Horsman, Doug E, Connors, Joseph M, Jones, Steven, Aparicio, Samuel, Hirst, Martin, Gascoyne, Randy D, Marra, Marco A

“…Marco Marra and colleagues identify somatic mutations in EZH2 in diffuse large B-cell lymphomas and follicular lymphomas. EZH2 is a histone methyltransferase…”
Get full text

Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study by Kridel, Robert, Chan, Fong Chun, Mottok, Anja, Boyle, Merrill, Farinha, Pedro, Tan, King, Meissner, Barbara, Bashashati, Ali, McPherson, Andrew, Roth, Andrew, Shumansky, Karey, Yap, Damian, Ben-Neriah, Susana, Rosner, Jamie, Smith, Maia A., Nielsen, Cydney, Giné, Eva, Telenius, Adele, Ennishi, Daisuke, Mungall, Andrew, Moore, Richard, Morin, Ryan D., Johnson, Nathalie A., Sehn, Laurie H., Tousseyn, Thomas, Dogan, Ahmet, Connors, Joseph M., Scott, David W., Steidl, Christian, Marra, Marco A., Gascoyne, Randy D., Shah, Sohrab P.

“…Follicular lymphoma (FL) is an indolent, yet incurable B cell malignancy. A subset of patients experience an increased mortality rate driven by two distinct…”
Get full text

Oncogenically active MYD88 mutations in human lymphoma by Ngo, Vu N., Young, Ryan M., Schmitz, Roland, Jhavar, Sameer, Xiao, Wenming, Lim, Kian-Huat, Kohlhammer, Holger, Xu, Weihong, Yang, Yandan, Zhao, Hong, Shaffer, Arthur L., Romesser, Paul, Wright, George, Powell, John, Rosenwald, Andreas, Muller-Hermelink, Hans Konrad, Ott, German, Gascoyne, Randy D., Connors, Joseph M., Rimsza, Lisa M., Campo, Elias, Jaffe, Elaine S., Delabie, Jan, Smeland, Erlend B., Fisher, Richard I., Braziel, Rita M., Tubbs, Raymond R., Cook, J. R., Weisenburger, Denny D., Chan, Wing C., Staudt, Louis M.

“…MYD88 signalling in cancer RNA interference screening and high-throughput RNA resequencing have been used to reveal oncogenic mutations in the signalling…”
Get full text

Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach by Hayden, Anna R, Tonseth, Petter, Lee, Derrick G, Villa, Diego, Gerrie, Alina S, Scott, David W, Freeman, Ciara L, Slack, Graham W, Farinha, Pedro, Skinnider, Brian, Yenson, Paul R, Benard, Francois, Lo, Andrea, Pickles, Tom, Wilson, Donald, Connors, Joseph M, Sehn, Laurie H, Savage, Kerry J

“…Cure rates for primary mediastinal large B-cell lymphoma (PMBCL) have improved with the integration of rituximab. However, the type of primary therapy and role…”
Get more information